ATE166877T1 - Bicyclische ansamycine und ihre verwendung als antitumormittel - Google Patents

Bicyclische ansamycine und ihre verwendung als antitumormittel

Info

Publication number
ATE166877T1
ATE166877T1 AT94913896T AT94913896T ATE166877T1 AT E166877 T1 ATE166877 T1 AT E166877T1 AT 94913896 T AT94913896 T AT 94913896T AT 94913896 T AT94913896 T AT 94913896T AT E166877 T1 ATE166877 T1 AT E166877T1
Authority
AT
Austria
Prior art keywords
tumor agents
ansamycins
bicyclic
bicyclic ansamycins
compounds
Prior art date
Application number
AT94913896T
Other languages
English (en)
Inventor
Rodney C Schnur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE166877T1 publication Critical patent/ATE166877T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT94913896T 1993-04-07 1994-03-14 Bicyclische ansamycine und ihre verwendung als antitumormittel ATE166877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (1)

Publication Number Publication Date
ATE166877T1 true ATE166877T1 (de) 1998-06-15

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913896T ATE166877T1 (de) 1993-04-07 1994-03-14 Bicyclische ansamycine und ihre verwendung als antitumormittel

Country Status (10)

Country Link
US (1) US5387584A (de)
EP (1) EP0693073B1 (de)
JP (1) JP2722280B2 (de)
AT (1) ATE166877T1 (de)
CA (1) CA2160137C (de)
DE (1) DE69410790T2 (de)
DK (1) DK0693073T3 (de)
ES (1) ES2116594T3 (de)
FI (1) FI106028B (de)
WO (1) WO1994022867A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP2002520369A (ja) 1998-07-17 2002-07-09 アメリカ合衆国 水溶性薬剤およびその製造方法
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
DE69928000T2 (de) * 1998-12-07 2006-06-08 Ecosmart Technologies Inc., Franklin Brustkrebsbehandlung mittels natürlicher ätherischer öle
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
JP4406205B2 (ja) * 2000-11-02 2010-01-27 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
WO2002036171A1 (en) 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
CA2447066A1 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1923061A1 (de) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Verfahren zur Herstellung eines 17-Allyl-amino-Geldanamycins (17-AAG) und anderer Ansamycine
ATE387198T1 (de) * 2001-09-24 2008-03-15 Conforma Therapeutic Corp Verfahren zur herstellung von 17-allyl-amino- geldanamycin (17-aag) und anderer ansamycine
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US20060014730A1 (en) * 2002-04-10 2006-01-19 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
EP2492261B1 (de) * 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analoga von benzochinonhaltigen Ansamycinen zur Behandlung von Krebs
US7491701B2 (en) * 2004-01-27 2009-02-17 Boys Town National Research Hospital Peptides that bind to HSP90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
MX2007011903A (es) 2005-03-30 2007-12-05 Conforma Therapeutics Corp Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
CA2603462A1 (en) * 2005-04-07 2006-10-09 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
AU2006242540A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either
US20060252740A1 (en) * 2005-04-29 2006-11-09 Johnson Robert G Jr Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
JP2008543941A (ja) * 2005-06-21 2008-12-04 インフィニティ・ディスカバリー・インコーポレイテッド アンサマイシン製剤およびその使用方法
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2007064926A2 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
EP2617428A1 (de) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mit mesenchymalen Stammzellen konditioniertes Medium
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101688227B (zh) 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
NZ580313A (en) * 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
EP2200653A2 (de) * 2007-09-10 2010-06-30 University of Massachusetts Antitumorale mittel gegen mitochondrien
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
JP5718648B2 (ja) 2008-02-22 2015-05-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子
US8716018B2 (en) 2008-03-17 2014-05-06 Agency For Science, Technology And Research Microcarriers for stem cell culture
AU2009243056B2 (en) * 2008-04-29 2015-05-14 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8778921B2 (en) 2008-10-15 2014-07-15 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
DK2699580T3 (en) 2011-04-22 2018-01-08 Joyant Pharmaceuticals Inc DIAZONAMI DISEASES
EP3795694A3 (de) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Verfahren für mit dem dna-erfassungspfad assoziierten leiden
WO2015013581A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
EP3525806B1 (de) 2016-10-12 2023-02-15 Agency For Science, Technology And Research Verfahren zur lyophilisierung eines exosoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
WO1994022867A1 (en) 1994-10-13
ES2116594T3 (es) 1998-07-16
FI941580L (fi) 1994-10-08
FI106028B (fi) 2000-11-15
EP0693073A1 (de) 1996-01-24
FI941580A0 (fi) 1994-04-06
DE69410790D1 (de) 1998-07-09
JPH08503960A (ja) 1996-04-30
EP0693073B1 (de) 1998-06-03
CA2160137C (en) 1999-02-09
DK0693073T3 (da) 1998-10-12
US5387584A (en) 1995-02-07
JP2722280B2 (ja) 1998-03-04
DE69410790T2 (de) 1998-10-01
CA2160137A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
ATE166877T1 (de) Bicyclische ansamycine und ihre verwendung als antitumormittel
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
DE69617273D1 (de) Heterocyclisch substituierte cyclopentanderivate.
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
ATE267200T1 (de) Bicyclische kinase inhibitoren
DE69721008D1 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DK0582789T3 (da) Nye (7-substitueret)-8-(substitueret)-9-(substitueret glycyl)amido-6-demethyl-6-deoxytetracycliner
ATE364592T1 (de) Tyrosinderivate
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
MY111201A (en) New imidazopyridines
ATE129497T1 (de) Bicyclische pyranderivate und ihre verwendung als 5-lipoxygenasehemmer.
ZA943744B (en) Therapeutic substituted guanidines
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
DE69416518D1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
NO20002191L (no) Dofetilid polymorfer

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee